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ABSTRACT: Invariant natural killer T cells (iNKT cells) are
restricted by CD1d molecules and activated upon CD1d-
mediated presentation of glycolipids to T cell receptors
(TCRs) located on the surface of the cell. Because the
cytokine response proﬁle is governed by the structure of the
glycolipid, we sought a method for labeling various glycolipids
to study their in vivo behavior. The prototypical CD1d agonist,
α-galactosyl ceramide (α-GalCer) 1, instigates a powerful
immune response and the generation of a wide range of
cytokines when it is presented to iNKT cell TCRs by CD1d molecules. Analysis of crystal structures of the TCR−α-GalCer−
CD1d ternary complex identiﬁed the α-methylene unit in the fatty acid side chain, and more speciﬁcally the pro-S hydrogen at
this position, as a site for incorporating a label. We postulated that modifying the glycolipid in this way would exert a minimal
impact on the TCR−glycolipid−CD1d ternary complex, allowing the labeled molecule to function as a good mimic for the CD1d
agonist under investigation. To test this hypothesis, the synthesis of a biotinylated version of the CD1d agonist threitol ceramide
(ThrCer) was targeted. Both diastereoisomers, epimeric at the label tethering site, were prepared, and functional experiments
conﬁrmed the importance of substituting the pro-S, and not the pro-R, hydrogen with the label for optimal activity. Signiﬁcantly,
functional experiments revealed that biotinylated ThrCer (S)-10 displayed behavior comparable to that of ThrCer 5 itself and
also conﬁrmed that the biotin residue is available for streptavidin and antibiotin antibody recognition. A second CD1d agonist,
namely α-GalCer C20:2 4, was modiﬁed in a similar way, this time with a ﬂuorescent label. The labeled α-GalCer C20:2 analogue
(11) again displayed functional behavior comparable to that of its unlabeled substrate, supporting the notion that the α-
methylene unit in the fatty acid amide chain should be a suitable site for attaching a label to a range of CD1d agonists. The
ﬂexibility of the synthetic strategy, and late-stage incorporation of the label, opens up the possibility of using this labeling
approach to study the in vivo behavior of a wide range of CD1d agonists.
■ INTRODUCTION
Invariant natural killer T (iNKT) cells are a distinctive subset of
T lymphocytes that express an invariant αβ T cell receptor
(TCR)1−3 and play an important role in infectious diseases,4,5
tumors,6,7 and autoimmune diseases,8 such as type I diabetes9,10
and lupus.11 In contrast to conventional CD4+ and CD8+ T
lymphocytes, which recognize foreign peptides bound to the
major histocompatibility complex (MHC) class I or MHC class
II molecule, iNKT cells recognize a range of foreign and
endogenous lipids bound to the nonpolymorphic CD1d
molecule.12,13 α-Galactosyl ceramide (α-GalCer) 1 is the
prototypical iNKT cell agonist (Figure 1). Its presentation by
CD1d molecules to TCRs located on iNKT cells results in a
powerful immune response involving the secretion of both pro-
inﬂammatory cytokines, including interferon-γ (IFNγ) (Th1-
type), and regulatory cytokines, including interleukin-4 (IL-4)
(Th2-type).14 α-GalCer 1 has served as a valuable template for
preparing structural analogues,15 such as compound OCH 2, a
more Th2 cytokine-biasing CD1d agonist,16,17 and the C-
glycosyl analogue of α-GalCer, 318,19 (Figure 1), which causes a
more Th1 cytokine-biasing immune response upon iNKT cell
activation.20−22 Threitol ceramide (ThrCer) 5 (Figure 1) also
successfully activates iNKT cells and, signiﬁcantly, overcomes
the problematic iNKT cell activation-induced anergy, which is
associated with iNKT cell stimulation by α-GalCer.23−25
Moreover, we have recently shown that amide isosteres of
this attractive nonglycosidic CD1d agonist can also be used to
bias the cytokine response toward Th1-type cytokines.26
All of the aforementioned glycolipids activate iNKT cells in a
similar fashion, namely through CD1d-mediated presentation
Received: October 10, 2012
Revised: February 21, 2013
Published: March 4, 2013
Article
pubs.acs.org/bc
© 2013 American Chemical Society 586 dx.doi.org/10.1021/bc300556e | Bioconjugate Chem. 2013, 24, 586−594
Terms of Use
to TCRs located on these cells; however, the origins of the
diﬀerent immune responses observed in each case remain
poorly understood.27 Thus, while CD1d and TCR binding
aﬃnity likely play a role,28,29 other factors, such as the cellular
location of glycolipid loading on the CD1d molecule, may also
be important in determining the ensuing immune response.30
For example, the Th2 cytokine-biasing α-GalCer analogues, 2
and 4, are loaded rapidly onto CD1d molecules located at the
surface of antigen-presenting cells.22,31 In contrast, the
disaccharide Gal(α1→2)α-GalCer requires cellular internal-
ization and lysosomal processing before loading can take
place.32 α-GalCer 1 also exhibits a requirement for endosomal
loading before surface presentation can take place, principally
within lipid rafts.22,33 To investigate the cellular behavior of
diﬀerent CD1d agonists, we sought a method for labeling
glycolipids, which would allow us to study the mechanisms that
control their uptake by professional antigen-presenting cells
(APC). Herein, we show that the methylene unit, and more
speciﬁcally the pro-S hydrogen, α to the amide functionality
provides a new site for appending a label to this class of
molecules. We describe a general and ﬂexible synthesis strategy
that allows structural variation in the glycolipid as well as late-
stage introduction of the label.
■ EXPERIMENTAL PROCEDURES
General Experimental Procedures. Melting points were
determined using open capillaries and are uncorrected. Infrared
spectra were recorded either neat or as thin ﬁlms between NaCl
disks. The intensity of each band is described as s (strong), m
(medium), or w (weak), with the preﬁx v (very) and suﬃx br
(broad) where appropriate. 1H NMR spectra were recorded at
500, 400, or 300 MHz. 13C NMR spectra were recorded at 125,
100, or 75 MHz. Chemical shifts are reported as δ values (parts
per million) referenced to the following solvent signals: CHCl3,
δH 7.26; CDCl3, δC 77.0; CH3OH, δH 3.31; CD3OD, δC 49.9.
For spectra recorded in a 1:2 CD3OD/CDCl3 mixed solvent
system, chemical shifts are referenced to the residual methanol
peak. The term “stack” is used to describe a region in which
resonances arising from nonequivalent nuclei are coincident
and multiplet, m, to describe a resonance arising from a single
nucleus (or equivalent nuclei) but where coupling constants
cannot be readily assigned. Mass spectra were recorded utilizing
electrospray ionization (and a MeOH mobile phase) and are
reported as m/z (%). HRMS spectra were recorded using a lock
mass incorporated into the mobile phase.
All reagents were obtained from commercial sources and
used without further puriﬁcation unless stated otherwise.
Anhydrous solvents were stored over 4 Å molecular sieves
and under an Ar atmosphere. All solutions are aqueous and
saturated unless stated otherwise.
All reactions were monitored by TLC using precoated
aluminum-backed ICN silica plates (60A F254) and visualized by
UV detection (at 254 nm) and staining with 5% phosphomo-
lybdic acid in EtOH (MPA spray). Column chromatography
was performed on silica gel (particle size of 40−63 μm mesh).
(2″S)-Biotinylated ThrCer [(S)-10]. A CuSO4 solution (12
μL of a 0.5 M solution, 6 μmol) and a sodium ascorbate
solution (26 μL of a 1.0 M solution, 26 μmol) were added to a
solution of azide (S)-17 (25 mg, 0.029 mmol) and alkyne 18
(13 mg, 0.029 mmol) in a t-BuOH/H2O mixture (1 mL, 1:1) at
room temperature. The reaction mixture was heated for 10 h at
50 °C, diluted with CHCl3 (10 mL), and washed with brine (3
mL). The phases were separated, and the aqueous layer was
extracted with CHCl3 (2 × 5 mL). The combined organic
layers were dried over Na2SO4, and the volatiles were removed
under reduced pressure. Puriﬁcation of the residue by ﬂash
column chromatography (10% MeOH in CHCl3) aﬀorded
triazole (S)-10 as a white paste (28 mg, 77%): Rf = 0.20 (10%
CH3OH in CHCl3); the poor solubility of this amphiphilic
compound at room temperature prevented us from obtaining
reliable optical rotation data; νmax (ﬁlm) 3332br (O−H, N−H),
1672s (CO) cm−1; 1H NMR (500 MHz, CDCl3/CD3OD,
2:1) δ 0.84 (t, J = 6.9 Hz, 6H, 2 × CH2CH3), 1.17−1.36 (stack,
70H), 1.38−1.46 (stack, 2H), 1.52−1.75 [stack, 4H, C(12‴)H2
(middle of stack), C(14‴)HaHb (LHS of stack), C(14‴)HaHb
(RHS of stack)], 2.01−2.09 [stack, 1H, C(3′′)HaHb], 2.10−
2.22 [stack, 3H, C(3′′)HaHb, C(11‴)H2], 2.71 [d, J = 12.8 Hz,
1H, C(18‴)HaHb], 2.89 [dd, J = 12.8, 5.0 Hz, 1H,
C(18‴)HaHb], 3.13−3.19 [m, 1H, C(15‴)H], 3.33−3.38
[stack, 2H, C(9‴)H2], 3.47−3.71 [stack, 18H, including C(1)
HaHb, C(4‴)H2], 3.73 [dd, J = 10.0, 5.0 Hz, 1H, C(1)HaHb],
3.75−3.79 (m, 1H), 4.17−4.22 [m, 1H, C(2)H], 4.30 [dd, J =
7.8, 4.3 Hz, 1H, C(16‴)H], 4.48 [dd, J = 7.8, 4.8 Hz, 1H,
C(17‴)H], 4.65 [s, 2H, C(3‴)H2], 5.27 [dd, J = 8.5, 6.5 Hz,
1H, C(2′′)H], 7.99 [s, 1H, C(1‴)H], exchangeable hydrogens
not observed; 13C NMR (125 MHz, CDCl3/CD3OD, 2:1) δ
14.3 [CH3, C(18), C(26′′) (resonance overlap)], 23.2 (CH2),
26.1 [CH2, C(12‴)], 26.2 (CH2), 26.4 (CH2), 28.8 [CH2,
C(14‴)], [29.1, 29.5, 29.87, 29.90, 30.1, 30.19, 30.22, 32.5
(CH2, alkyl chain, some resonance overlap)], 36.2 [CH2,
C(11‴)], 39.8 [CH2, C(9‴)], 40.8 [CH2, C(18‴)], 51.3 [CH,
C(2)], 56.3 [CH, C(15‴)], 60.9 [CH, C(17‴)], 62.6 [CH,
C(16‴)], 63.9 [CH2, C(4′)], 64.7 [CH, C(2′′)], 64.8 [CH2,
C(3‴)], 70.17 [CH2, C(4‴)], 70.24 (CH2), 70.5 (CH2), 70.6
(CH2), 70.8 (CH), 70.99 (CH2), 71.03 (CH2), 72.5 (CH), 72.8
(CH), 73.4 [CH2, C(1′)], 75.0 [CH, C(3)], 123.3 [CH,
C(1‴)], 145.3 [C, C(2‴)], 165.1 (C, NHCONH), 169.1 [C,
C(1′′)], 175.2 [C, C(10‴)]; MS (TOF ES+) m/z 1276.8 ([M
+ Na]+, 100%), 649.9 (7), 398.1 (5); HRMS (TOF ES+) calcd
for C67H127N7O12SNa [M + Na]
+ 1276.9161, found 1276.9166.
Fluor 488-Labeled α-GalCer (11) (1:1 mixture of
regioisomers in the label). A CuSO4 solution (6 μL of a
0.5 M solution, 3 μmol) and a sodium ascorbate solution (13
μL of a 1.0 M solution, 13 μmol) were added to a solution of
azide 22 (1.4 mg, 1.7 μmol) and alkyne 23 (1.0 mg, 1.7 μmol)
in a t-BuOH/H2O mixture (0.5 mL, 1:1) at room temperature.
Figure 1. Glycolipid agonists of CD1d.
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The reaction mixture was heated for 10 h at 50 °C, diluted with
CHCl3 (5 mL), and washed with brine (1.5 mL). The phases
were separated, and the aqueous layer was extracted with
CHCl3 (2 × 2.5 mL). The combined organic layers were dried
over Na2SO4, and the volatiles were removed under reduced
pressure. Puriﬁcation of the residue by ﬂash column
chromatography (CHCl3/MeOH/H2O, 65:25:4) aﬀorded
triazole 11 as a red solid (1.4 mg, 59%, 1:1, mixture of
regioisomers in the label): Rf = 0.32 (CHCl3/MeOH/H2O,
65:25:4); 1H NMR (400 MHz, CDCl3/CD3OD, 2:1) δ 0.83 (t,
J = 6.7 Hz, 3H), 0.84 (t, J = 6.7 Hz, 3H), 1.10−1.39 (stack,
44H), 1.40−1.65 (m, 1H), 1.65−1.89 (m, 1H), 1.92−2.03
(stack, 5H), 2.12−2.30 (1H, m), 2.66−2.79 (stack, 2H), 3.46−
3.79 (stack, 22H), 3.86 (dd, J = 10.8, 4.8 Hz, 1H), 3.90 (br s,
1H), 4.12−4.22 (m, 1H), 4.55−4.67 (m, 2H), 4.88 (d, J = 3.6
Hz, 1H), 5.21−5.41 (stack, 5H), 6.63−6.77 (stack, 4H), 6.96−
7.09 (stack, 2H), 7.31 (d, J = 9.0 Hz, 0.5H), 7.76 (br s, 0.5H),
7.92 (s, 1H), 8.13−8.24 (m, 1H), 8.31 (d, J = 9.0 Hz, 0.5H),
8.72 (br s, 0.5H); MS (TOF ES−) m/z 1396.8 ([M − H]−,
10%), 1218.8 (5, [M − galactose]−), 1004.6 (15), 915.6 (25),
850.7 (65), 815.7 (35), 451.5 (95), 423.5 (100), 179.1 (20,
[galactose]−).
Experimental procedures and characterization data for
compounds 25, 26, 13a, 13b, 14, (2S)-methyl 2-azidohex-
acosanoate, (S)-15, (S)-17, 18, (S)-10, (rac)-15, 17, 10, 11,
27−30, and 20 can be found in the Supporting Information.
Mice, Cell Lines, and Cultures. C57 BL/6 mice were used
in accordance with the Animals (Scientiﬁc Procedures) Act
1986. iNKT cells were generated from healthy blood donors as
previously described.29,34 iNKT cell cultures were maintained in
Roswell Park Memorial Institute-1640 (RPMI-1640) supple-
mented with 2 mM L-glutamine, 1% nonessential amino acids,
1% pyruvate, 1% Pen/Strep, 5% human serum (Gibco), and
500 units of IL-2/mL. Functional assays and C1R CD1d lipid
pulsing were performed in RPMI-1640 supplemented with 2
mM L-glutamine, 1% nonessential amino acids, 1% pyruvate,
1% Pen/Strep (Gibco), and 10% fetal calf serum (FCS)
(Sigma).
iNKT Cell TCR Tetramer Staining. The synthesis of
soluble iNKT TCR heterodimers has been described
previously.29 C1R CD1d cells were pulsed with diﬀerent
concentrations of the indicated iNKT cell agonists for 16 h.
Cells were washed with a PBS/10% FCS mixture and incubated
with 0.5−1.0 μg of iNKT cell TCR tetramer or equivalent
amounts of streptavidin on ice for 30 min. Cells were also
stained with an antibiotin FITC-conjugated antibody (Jackson
Laboratories) for 30 min on ice. Cells were washed, and
samples were analyzed on a FACScalibur instrument (BD).
Data analysis was performed using Flowjo (Treestar).
iNKT Cell Activation and Cytokine Detection. A
polyclonal human iNKT cell line, or a mouse iNKT cell
hybridoma (DN32), was incubated for 36 h with monocyte-
derived DCs in the presence or absence of iNKT cell agonists
and the level of cytokines released by iNKT cells measured in
the supernatants. The concentrations of human IFN-γ and
mouse IL-2 were measured by an enzyme-linked immunosorb-
ent assay (ELISA) as previously described.24 All samples were
tested at the same time on a single ELISA plate for each assay.
In addition, for in vitro activation of mouse iNKT cells, 5 × 105
splenocytes from C57 BL/6 mice were pulsed with various
concentrations of lipids for 48 h. Supernatants were removed,
and the presence of IFN-γ was determined by an ELISA.24
■ RESULTS AND DISCUSSION
Chemical labeling studies of α-GalCer 1 have previously
introduced the label at C(6)OH of the galactose residue;35,36
however, this strategy was rejected for a number of reasons.
First, we desired a labeling methodology that could be
employed generally for a range of CD1d agonists, including
truncated sugar analogues such as ThrCer 5, which lack a C(6)
tethering site.37 Second, crystal structures of C(6)-derivatized
α-GalCer analogues reveal the functionality at C(6) can exploit
a hydrophobic binding site in CD1d,38 which is not available to
α-GalCer, and that this additional binding aﬀects the biological
activity,39 something to be avoided when trying to retain the
activity of the agonist under investigation. Labels have also been
appended to the terminus of the N-acyl chain of α-GalCer;40−42
however, we reasoned that a CD1d agonist modiﬁed in this
fashion would result in the label being buried deep inside the A′
pocket of the protein molecule. This might signiﬁcantly alter
the binding conformation of the glycolipid under study, and
analogues biotinylated in this way would mean the biotin label
would likely be unavailable for streptavidin or antibiotin
antibody recognition. Analysis of X-ray structures of the
TCR−α-GalCer−CD1d complex,43 and similar ternary com-
plexes involving α-GalCer analogues,40−42 reveals the glycolipid
binds to the CD1d molecule in a similar fashion, with the N-
acyl chain occupying the hydrophobic A′ pocket of the protein
and the ceramide base the less voluminous F′ pocket, leaving
the polar sugar residue surface-exposed for TCR recognition.
For our purposes, this analysis allowed us to identify the α-
methylene unit of the amide chain, and speciﬁcally the pro-S
hydrogen at this position, as being amenable to substitution
because this group is directed out toward bulk solvent in the
ternary complex (Figure 2). We postulated that a label
incorporated into this position would protrude away from the
ternary TCR−glycolipid−CD1d complex without deleteriously
aﬀecting its conformation and, at the same time, also permit
recognition of a tethered reporter group such as a biotin label.
Because of the challenging practical issues associated with
handling glycolipids, and the high cost of many labels, our
chosen synthetic strategy for the two targets, (S)-10 [note that
the (S) label denotes the absolute conﬁguration of the
stereogenic center located α to the amide carbonyl group]
Figure 2. Substituents appended to the pro-S hydrogen substituent in
the α position of the N-acyl chain (highlighted with the arrow) should
extend beyond and away from the TCR−glycolipid−CD1d recog-
nition site (structure taken from Protein Data Bank entry 2PO643).
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and 11, would incorporate the label at a late stage of the
synthesis and use Click chemistry to assemble the components,
ideally using an already fully deprotected glycolipid (Scheme
1). An oligo(ethylene glycol) spacer unit would be employed as
Scheme 1. General Retrosynthetic Strategy for the Assembly of Labeled Glycolipids and Target Molecules (S)-10 and 11
Scheme 2. Synthesis of Biotinylated ThrCer (S)-10
Figure 3. iNKT cell recognition of ThrCer 5 and biotinylated ThrCer
analogues, tested as single epimers (S)-10 and (R)-10 and as a 1:1
mixture. (a) Recognition of ThrCer and biotinylated analogues by
human iNKT TCR assessed by FACS analysis following co-incubation
of ﬂuorescent human iNKT cell TCR and C1R cells loaded with
indicated lipids. (b) Activation of iNKT cell hybridoma following
overnight culture with dendritic cells loaded with ThrCer and
biotinylated analogues as determined by IL-2 production in the
supernatant. Data presented are means of triplicate wells and are
representative of three independent experiments.
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a linker,44 to ensure the label extends suﬃciently from the TCR
recognition site so as not to interrupt antigen presentation. We
expected such a linker might also impart favorable solubility
properties on the ﬁnal products.45,46 Further disconnection of
amide 6 revealed α-azido acid 7, which would be coupled
selectively with the amino functionality embedded in 8. Amine
8 would be assembled from phytosphingosine-derived glycosyl
acceptor 9,25 and an appropriate glycosyl donor.
The synthesis of our ﬁrst target, biotinylated ThrCer (S)-10,
is detailed in Scheme 2. Enantiopure (S)-2-azidohexacosanoic
acid (S)-15 was readily accessed from Schöllkopf’s auxiliary
12;47−49 thus, treatment of bis-lactim 12 with BuLi, followed by
reaction of the resulting lithiated intermediate with 1-
iodotetracosane,50 aﬀorded the alkylation product as a
separable 15:1 mixture of diastereoisomers. The desired
major diastereoisomer 13 was then hydrolyzed to aﬀord α-
amino ester 14.49 Subsequent diazo transfer51 and ester
hydrolysis49 aﬀorded α-azido acid (S)-15, which was converted
into the corresponding acid chloride and coupled with amine
16 (see the Supporting Information) under biphasic reaction
conditions to aﬀord amide (S)-17 [note that the (S) label
denotes the absolute conﬁguration of the stereogenic center
located α to the amide carbonyl group] in good yield. While
there is the potential for racemization of the α-azido acid
chloride coupling partner, a comparison of the 13C NMR data
of (S)-17 with those of (R/S)-17 [note that the (R/S) label
denotes a 1:1 mixture of diastereoisomers epimeric at the
stereogenic center located α to the amide carbonyl group in
17] showed that no epimerization had occurred at the α-
stereogenic center under the acylation reaction conditions (see
the Supporting Information). In the ﬁnal step, Huisgen [3+2]
dipolar cycloaddition52,53 of the azide in (S)-17 with alkyne 18
(see the Supporting Information) provided our target,
biotinylated ThrCer (S)-10, in 77% isolated yield.
Before progressing with biological analysis of biotinylated
ThrCer (S)-10 and to assess the importance of obtaining the
correct stereochemistry at the tethering site, we used racemic 2-
azidohexacosanoic acid in the synthetic sequence summarized
in Scheme 2 to access the diastereoisomeric end product (R)-
10 [epimeric at the tethering site; the (R) label denotes the
Figure 4. In vitro activation of human iNKT cells by ThrCer 5 and
biotinylated ThrCer 10 (epimeric mixture). A human iNKT cell line
was incubated with C1R CD1d cells pulsed either with ThrCer 5 (■)
or with biotinylated ThrCer 10 (epimeric mixture) (□). IFN-γ
secretion was analyzed after 36 h by an ELISA. The results are
representative of three separate experiments.
Figure 5. Detection of biotinylated ThrCer 10 (1:1 epimeric mixture) on the surface of APCs. C1R CD1d cells were pulsed with the indicated
concentrations of biotinylated ThrCer for 16 h and then stained with (a) soluble iNKT cell TCR (APC), (b) ﬂuorescent streptavidin (APC), or (c)
the antibiotin antibody [labeled with ﬂuorescein isothiocyanate (FITC)]. Panels a−c depict histogram overlays of the indicated ﬂuorescence
intensities. The dot plot shown in panel d depicts a double staining with the soluble iNKT cell TCR (APC) and antibiotin antibody (FITC). The
results are representative of two separate experiments.
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absolute conﬁguration of the stereogenic center located α to
the amide carbonyl group], which could be separated from its
epimer (S)-10 by careful column chromatography.
A 1:1 epimeric mixture (S/R)-10 and the single epimers of
biotinylated ThrCer, (S)-10 and (R)-10, were next tested
separately for their ability to be loaded onto human CD1d
molecules as deﬁned by staining with tetrameric human iNKT
cell TCR29,54 (Figure 3a) and recognized by murine iNKT cells
(Figure 3b).23 In the ﬁrst experiment, C1R-human CD1d cells
were loaded with ThrCer 5 and the corresponding biotinylated
analogues and then incubated with ﬂuorescent human iNKT
cell TCR. Subsequent ﬂuorescence-activated cell sorting
(FACS) analysis revealed that (S)-10 and the epimeric mixture
behaved like unlabeled ThrCer 5 in their ability to be
recognized by the iNKT cell TCR, while the activity of the
(R)-epimer, (R)-10, used on its own, was slightly attenuated
(Figure 3a). In a second assay, C1R-mouse CD1d cells were
ﬁrst loaded with ThrCer 5 and the corresponding biotinylated
analogues and then cultured overnight in the presence of iNKT
cell hybridoma (DN32). iNKT cell activation was assessed by
measuring interleukin-2 (IL-2) production by an ELISA.55,56
Once again, and in line with our predictions, the two epimeric
biotinylated ThrCer analogues behaved diﬀerently in their
ability to activate iNKT cells, and in accord with our
hypothesis, the labeled analogue, possessing the (S)-conﬁg-
uration at the tethering site, behaved signiﬁcantly better than its
(R)-epimer (Figure 3b). In this experiment, the more active
labeled epimer, (S)-10, appears to show greater activity than
unlabeled ThrCer itself at high lipid concentrations. Modifying
the structure of any agonist is likely to have some impact on the
activity, and in this experiment, our labeled analogue is no
diﬀerent. The greater activity compared with that of its
unlabeled analogue (ThrCer) in this assay is interesting, and
we postulate that diﬀerences in lipid processing (i.e., uptake and
presentation on CD1d molecules) of murine and human APCs
and the subsequent iNKT cell TCR may explain these
observations. Although there was a diﬀerence in activity
between the two epimers, the biological results using a 1:1
epimeric mixture (in which the concentration of the more
active epimer is halved) proved to be similar to those using the
single epimer (S)-10, and for this reason, all subsequent
experiments described below were performed with the more
readily accessed epimeric mixture.
Further experiments using human iNKT cells conﬁrmed that
the presence of the biotin label does not aﬀect optimal loading
onto CD1d molecules and presentation to human iNKT cells.
To this end, C1R-hCD1d cells were pulsed with labeled (10)
and unlabeled ThrCer (5), and their ability to be recognized by
iNKT cells was assessed by measuring the release of IFN-γ by
an ELISA after the cells had been cultured for 36 h (Figure 4).
The similar response proﬁle observed with ThrCer 5 and its
biotinylated analogue (10) indicated that human iNKT cells are
sensitized to a similar level, and that the biotin label does not
aﬀect signiﬁcantly CD1d loading or iNKT cell presentation.
To further investigate the availability of the biotin on the cell
surface of the APC, C1R CD1d cells were pulsed with
biotinylated ThrCer 10 for 16 h before being stained with
ﬂuorescent streptavidin (Figure 5b), the antibiotin antibody
(Figure 5), or soluble iNKT cell TCR (Figure 5a).29 These
results demonstrate that (i) the label can be detected by these
two commonly used detection methods, opening up the
possibility of using these as staining reagents to identify
biotinylated ThrCer-pulsed cells, (ii) the TCR recognizes the
labeled glycolipid in the context of CD1d molecules, and (iii)
we are able to perform double staining using both soluble
iNKT cell TCR and antibiotin antibody showing that the
glycolipid−CD1d complex and label can be detected at the
same time (Figure 5d).
Scheme 3. Synthesis of Fluor 488-Labeled α-GalCer C20:2
11
Figure 6. In vitro activation of iNKT cells by Fluor 488-labeled α-
GalCer C20:2 11. Splenocytes from C57 BL/6 mice were cultured in
the presence of various concentrations of either unlabeled 4 or Fluor
488-labeled α-GalCer C20:2 11 for 48 h. The supernatants were then
analyzed for the presence of IFN-γ by an ELISA. Data are means of
duplicate wells and are representative of two independent experiments.
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Next, to assess the generality of our glycolipid labeling
strategy, we chose to introduce a ﬂuorescent label into a second
CD1d agonist, namely the Th2 cytokine-biasing CD1d agonist
α-GalCer C20:2 (4). The synthesis of labeled α-GalCer C20:2,
11, is summarized in Scheme 3. α-Galactoside 20, prepared in
six steps from phytosphingosine 19 using our recently
developed methodology for accessing 6″-azido-6″-deoxy-α-
GalCer analogues,57 was coupled with enantiomerically pure
α-azido acid chloride 21, accessed from the Schöllkopf auxiliary
and linoleyl bromide (see the Supporting Information), to
provide amide 22 as an advanced intermediate in excellent
yield. Subsequent Click reaction with alkyne 23 aﬀorded our
target, ﬂuorescently labeled α-GalCer C20:2, 11.
The ability of α-GalCer C20:2 (4) and labeled α-GalCer
C20:2 (11) to activate murine iNKT cells was assessed (Figure
6).24 To this end, mouse splenocytes were cultured separately
with various concentrations of α-GalCer C20:2 4, and the
corresponding Fluor 488-labeled analogue 11, and then the
presence of IFN-γ was detected in the culture supernatant by an
ELISA. As for the biotinylated ThrCer analogue, these results
showed that the label does not signiﬁcantly aﬀect the behavior
of α-GalCer C20:2 in its ability to activate murine iNKT cells,
especially at low biologically relevant concentrations of the
glycolipid, opening up the possibility of using this labeled
analogue to study the biology of the important Th2 cytokine-
biasing CD1d agonist α-GalCer C20:2 4.
■ CONCLUSIONS
In summary, we have shown that the pro-S hydrogen site in the
α-methylene of the N-acyl chain of two important CD1d
agonists, namely, ThrCer 5 and α-GalCer C20:2 4, can be used
to append a label. In the two examples targeted, the functional
activity of the labeled molecules was comparable in the human
and mouse systems to that displayed by the unlabeled
molecules, which should allow us to use these labeled analogues
to study their traﬃcking behavior in vivo. The synthesis of both
epimers of the biotinylated ThrCer analogue conﬁrmed the
importance of choosing the correct conﬁguration at the
tethering site, which was in accord with our predictions based
on X-ray crystallographic structure analyses of the TCR−α-
GalCer−CD1d ternary complex. Moreover, we were able to
show for the ﬁrst time that a biotin label attached to ThrCer
remains accessible even when the soluble iNKT TCR is bound
to the CD1d−lipid complex, as demonstrated by the double
staining with soluble iNKT TCR and an antibiotin antibody.
Because our synthetic strategy allows the incorporation of any
sugar headgroup and fatty acid acyl chain and involves the late-
stage introduction of the label from an advanced intermediate,
we expect other CD1d agonists (and potentially other bioactive
glycolipids) can be labeled using this approach.
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Dauchez, M., Renault, J.-H., Monneaux, F., and Haudrechy, A. (2012)
The stimulating adventure of KRN7000. Org. Biomol. Chem. 9, 3080−
3104.
(16) Miyamoto, K., Miyake, S., and Yamamura, T. (2001) A synthetic
glycolipid prevents autoimmune encephalomyelitis by inducing TH2
bias of natural killer T cells. Nature 413, 531−534.
(17) Oki, S., Tomi, C., Yamamura, T., and Miyake, S. (2005)
Preferential Th2 polarization by OCH is supported by incompetent
NKT cell induction of CD40L and following production inflammatory
cytokines by bystander cells in vivo. Int. Immunol. 17, 1619−1629.
(18) Schmieg, J., Yang, G., Franck, R. W., and Tsuji, M. (2003)
Superior protection against malaria and melanoma metastases by a C-
glycoside analogue of the natural killer T cell ligand α-galactosylcer-
amide. J. Exp. Med. 198, 1631−1641.
(19) Yang, G., Schmieg, J., Tsuji, M., and Franck, R. W. (2004) The
C-glycoside analogue of the immunostimulant α-galactosylceramide
(KRN7000): Synthesis and striking enhancement of activity. Angew.
Chem., Int. Ed. 43, 3818−3822.
(20) Araki, M., Miyake, S., and Yamamura, T. (2008) Synthetic
glycolipid ligands for human iNKT cells as potential therapeutic agents
for immunotherapy. Curr. Med. Chem. 15, 2337−2345.
(21) Venkataswamy, M. M., Baena, A., Goldberg, M. F., Bricard, G.,
Im, J. S., Chan, J., Reddington, F., Besra, G. S., Jacobs, W. R., and
Porcelli, S. A. (2009) Incorporation of NKT cell-activating glycolipids
enhances immunogenicity and vaccine efficacy of Mycobacterium bovis
bacillus Calmette-Guerin. J. Immunol. 183, 1644−1656.
(22) Im, J. S., Arora, P., Bricard, G., Molano, A., Venkataswamy, M.
M., Baine, I., Jerud, E. S., Goldberg, M. F., Baena, A., Yu, K. O.,
Ndonye, R. M., Howell, A. R., Yuan, W. M., Cresswell, P., Chang, Y.-
T., Illarionov, P. A., Besra, G. S., and Porcelli, S. A. (2009) Kinetics and
cellular site of glycolipid loading control the outcome of natural killer
T cell activation. Immunity 30, 888−898.
(23) Silk, J. D., Salio, M., Reddy, B. G., Shepherd, D., Gileadi, U.,
Brown, J., Masri, S. H., Polzella, P., Ritter, G., Besra, G. S., Jones, E. Y.,
Schmidt, R. R., and Cerundolo, V. (2008) Nonglycosidic CD1d lipid
ligands activate human and murine invariant NKT cells. J. Immunol.
180, 6452−6456.
(24) Reddy, B. G., Silk, J. D., Salio, M., Balamurugan, R., Shepherd,
D., Ritter, G., Cerundolo, V., and Schmidt, R. R. (2009) Nonglycosidic
CD1d lipid ligands activate human and murine invariant NKT cells.
ChemMedChem 4, 171−178.
(25) Garcia-Diaz, Y. R., Wojno, J., Cox, L. R., and Besra, G. S. (2009)
Synthesis of threitol ceramide and [14C]threitol ceramide, non-
glycosidic analogues of the potent CD1d antigen α-galactosyl
ceramide. Tetrahedron: Asymmetry 20, 747−753.
(26) Wojno, J., Jukes, J.-P., Ghadbane, H., Shepherd, D., Besra, G. S.,
Cerundolo, V., and Cox, L. R. (2012) Amide analogues of CD1d
agonists modulate iNKT-cell-mediated cytokine production. ACS
Chem. Biol. 7, 847−855.
(27) Sullivan, B. A., Nagarajan, N. A., Wingender, G., Wang, J., Scott,
I., Tsuji, M., Franck, R. W., Porcelli, S. A., Zajonc, D. M., and
Kronenberg, M. (2010) Mechanisms for glycolipid antigen-driven
cytokine polarization by Vα14i NKT cells. J. Immunol. 184, 141−153.
(28) Oki, S., Chiba, A., Yamamura, Y., and Miyake, S. (2004) The
clinical implication and molecular mechanism of preferential IL-4
production by modified glycolipid-stimulated NKT cells. J. Clin. Invest.
113, 1631−1640.
(29) McCarthy, C., Shepherd, D., Fleire, S., Stronge, V. S., Koch, M.,
Illarionov, P. A., Bossi, G., Salio, M., Denkberg, G., Reddington, F.,
Tarlton, A., Reddy, B. G., Schmidt, R. R., Reiter, Y., Griffiths, G. M.,
Van Der Merwe, P. A., Besra, G. S., Jones, E. Y., Batista, F. D., and
Cerundolo, V. (2007) The length of lipids bound to human CD1d
molecules modulates the affinity of NKT cell TCR and the threshold
of NKT cell activation. J. Exp. Med. 204, 1131−1144.
(30) Venkataswamy, M. M., and Porcelli, S. A. (2010) Lipid and
glycolipid antigens of CD1d-restricted natural killer T cells. Semin.
Immunol. 22, 68−78.
(31) Yu, K. O. A., Im, J. S., Molano, A., Dutronc, Y., Illarionov, P. A.,
Forestier, C., Fujiwara, N., Arias, I., Miyake, S., Yamamura, T., Chang,
Y. T., Besra, G. S., and Porcelli, S. A. (2005) Modulation of CD1d-
restricted NKT cell responses by using N-acyl variants of α-
galactosylceramides. Proc. Natl. Acad. Sci. U.S.A. 102, 3383−3388.
(32) Prigozy, T. I., Naidenko, O., Qasba, P., Elewaut, D., Brossay, L.,
Khurana, A., Natori, T., Kozeuka, Y., Kulkarni, A., and Kronenberg, M.
(2001) Glycolipid antigen processing for presentation by CD1d
molecules. Science 291, 664−667.
(33) Park, Y.-K., Lee, J.-W., Ko, Y.-G., Hong, S., and Park, S.-H.
(2005) Lipid rafts are required for efficient signal transduction by
CD1d. Biochem. Biophys. Res. Commun. 327, 1143−1154.
(34) Salio, M., Shepherd, D., Dunbar, P. R., Palmowski, M., Murphy,
K., Wu, L. J., and Cerundolo, V. (2001) Mature dendritic cells prime
functionally superior melan-A-specific CD8+ lymphocytes as compared
with nonprofessional APC. J. Immunol. 167, 1188−1197.
(35) Xia, C., Zhang, W., Zhang, Y., Woodward, R. L., Wang, J., and
Wang, P. G. (2009) Facile synthesis of biotin labelled α-
galactosylceramide as antigen for invariant natural killer T cells.
Tetrahedron 65, 6390−6395.
(36) Zhou, X.-T., Forestier, C., Goff, R. D., Li, C., Teyton, L.,
Bendelac, A., and Savage, P. B. (2002) Synthesis and NKT cell
stimulating properties of fluorophore- and biotin-appended 6″-amino-
6″-deoxy-galactosylceramides. Org. Lett. 4, 1267−1270.
(37) All three alcohol functionalities in ThrCer are important for
TCR recognition (unpublished results).
(38) Aspeslagh, S., Li, Y., Yu, E. D., Pauwels, N., Trappeniers, M.,
Girardi, E., Decruy, T., Van Beneden, K., Venken, K., Drennan, M.,
Leybaert, L., Wang, J., Franck, R. W., Van Calenburgh, S., Zajonc, D.
M., and Elewaut, D. (2011) Galactose-modified iNKT cell agonists
stabilized by an induced fit of CD1d prevent tumour metastasis.
EMBO J. 30, 2294−2305.
(39) Trappeniers, M., Van Beneden, K., Decruy, T., Hillaert, U.,
Linclau, B., Elewaut, D., and Van Calenbergh, S. (2008) 6′-Derivatised
α-GalCer analogues capable of inducing strong CD1d-mediated Th1-
biased NKT cell responses in mice. J. Am. Chem. Soc. 130, 16468−
16469.
(40) Sakai, T., Ehara, H., and Koezuka, Y. (1999) Synthesis of NBD-
α-galactosylceramide and its immunologic properties. Org. Lett. 1,
359−361.
(41) Sakai, T., Naidenko, O. V., Iijima, H., Kronenberg, M., and
Koezuka, Y. (1999) Syntheses of biotinylated α-galactosylceramides
and their effects on the immune system and CD1 molecules. J. Med.
Chem. 42, 1836−1841.
(42) Vo-Hoang, Y., Micouin, L., Ronet, C., Gachelin, G., and Bonin,
M. (2003) Total enantioselective synthesis and in vivo biological
Bioconjugate Chemistry Article
dx.doi.org/10.1021/bc300556e | Bioconjugate Chem. 2013, 24, 586−594593
evaluation of a novel fluorescent BODIPY α-galactosylceramide.
ChemBioChem 4, 27−33.
(43) Borg, N. A., Wun, K. S., Kjer-Nielsen, L., Wilce, M. C., Pellicci,
D. G., Koh, R., Besra, G. S., Bharadwaj, M., Godfrey, D. I., McCluskey,
J., and Rossjohn, J. (2007) CD1d−lipid-antigen recognition by the
semi-invariant NKT T-cell receptor. Nature 448, 44−49.
(44) Poly(ethylene glycol) linkers are commonly used. See, for
example: Natarajan, A., Du, W., Xiong, C.-Y., DeNardo, G. L.,
DeNardo, S. J., and Gervay-Hague, J. (2007) Construction of Di-scFv
through a trivalent alkyne-azide 1,3-dipolar cycloaddition. Chem.
Commun., 695−697.
(45) Veronese, F. M., and Pasut, G. (2005) PEGylation, successful
approach to drug delivery. Drug Discovery Today 10, 1451−1458.
(46) Zalipsky, S., and Harris, J. M. (1997) in Introduction to chemistry
and biological applications of poly(ethylene glycol), ACS Symposium
Series, Vol. 680, pp 1−13, American Chemical Society, Washington,
DC.
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